Warsaw - Delayed Quote PLN

Molecure S.A. (MOC.WA)

6.00

-0.20

(-3.23%)

At close: June 6 at 5:01:58 PM GMT+2

Key Events

Loading Chart for MOC.WA

Previous Close 6.20
Open 6.18
Bid 5.94 x --
Ask 6.00 x --
Day's Range 5.90 - 6.20
52 Week Range 5.40 - 16.70
Volume 29,169
Avg. Volume 26,307
Market Cap (intraday) 121.219M
Beta (5Y Monthly) 2.36
PE Ratio (TTM) --
EPS (TTM) -1.40
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 18.25

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.

94

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 6/6/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

MOC.WA

40.59%

MSCI WORLD (^990100-USD-STRD)

5.27%

1-Year Return

MOC.WA

59.02%

MSCI WORLD (^990100-USD-STRD)

12.38%

3-Year Return

MOC.WA

78.87%

MSCI WORLD (^990100-USD-STRD)

0.00%

5-Year Return

MOC.WA

44.44%

MSCI WORLD (^990100-USD-STRD)

72.70%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

6.00

-3.23%

Mkt Cap PLN 121.219M

Industry Biotechnology

Ryvu Therapeutics S.A.

30.25

+0.83%

Mkt Cap PLN 699.262M

Industry Biotechnology

106.60

+3.50%

Mkt Cap PLN 524.948M

Industry Biotechnology

Verrica Pharmaceuticals Inc.

0.6116

+4.82%

Mkt Cap 56.567M

Industry Biotechnology

PTC Therapeutics, Inc.

52.13

+0.77%

Mkt Cap 4.132B

Industry Biotechnology

Akero Therapeutics, Inc.

54.28

+0.63%

Mkt Cap 4.327B

Industry Biotechnology

9.61

+14.95%

Mkt Cap 482.041M

Industry Biotechnology

Rocket Pharmaceuticals, Inc.

3.0650

+10.65%

Mkt Cap 330.217M

Industry Biotechnology

Altimmune, Inc.

5.62

+2.93%

Mkt Cap 455.821M

Industry Biotechnology

aTyr Pharma, Inc.

5.38

+0.56%

Mkt Cap 478.844M

Industry Biotechnology

Viking Therapeutics, Inc.

27.83

+2.92%

Mkt Cap 3.126B

Industry Biotechnology

Valuation Measures

    Annual 

As of 6/6/2025

Market Cap

121.22M
Enterprise Value

87.25M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

1.23
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-17.68%
Return on Equity (ttm)

-30.82%
Revenue (ttm)

3.49M
Net Income Avi to Common (ttm)

-29.63M
Diluted EPS (ttm)

-1.40

Balance Sheet and Cash Flow

Total Cash (mrq)

40.66M
Total Debt/Equity (mrq)

6.81%
Levered Free Cash Flow (ttm)

-34.68M

RVU.WA Ryvu Therapeutics S.A.

30.25

+0.83%

CCC.WA CCC S.A.

197.75

-2.01%

CTX.WA Captor Therapeutics Spolka Akcyjna

32.30

0.00%

MAB.WA Mabion S.A.

9.64

-0.62%

PUR.WA Pure Biologics S.A.

4.8800

-2.20%